ロード中...
IMMU-37. VEMURAFENIB ENHANCES THE CYTOTOXICITY OF NY-ESO-1 TCR ENGINEERED T-CELLS FOR BRAF MUTANT BRAIN TUMORS
INTRODUCTION: Missense BRAF mutations are found in a significant portion of pediatric brain tumors, leading to constitutive MAPK pathway activation. By combining immunotherapy with BRAF targeted therapies like vemurafenib, an opportunity might exist to mitigate innate cellular immune escape mechanis...
保存先:
| 出版年: | Neuro Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216357/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.540 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|